Journal of Diagnostics Concepts & Practice >
Potential biomarkers for prediction of the efficacy and safety of CAR T cell treatment in systemic lupus erythematosus
Received date: 2024-04-23
Accepted date: 2024-05-23
Online published: 2024-06-25
Systemic lupus erythematosus (SLE) is a complex autoimmune disease for which traditional treatments often show limited efficacy in severe and refractory cases. Recently, chimeric antigen receptor (CAR) T cell therapy has emerged as a novel immunotherapy strategy, demonstrating significant efficacy in preliminary studies for SLE treatment. Biomarkers are crucial for the precise assessment of treatment efficacy and safety. Biomarkers for monitoring the efficacy of CAR T cell therapy include traditional markers and markers related to CAR T therapy. Traditional markers for SLE disease monitoring, such as decreased titers of serum anti-double-stranded DNA, anti-single-stranded DNA, anti-nucleosome autoantibodies, normalization of serum complement levels, and improvement of urine protein/creatinine ratio, indicate that the disease is effectively controlled and can still be used for baseline follow-up and disease monitoring during CAR T cell therapy. B cell markers indicating effective CAR T therapy include a decrease in the number of B cells after infusion, a B cell phenotype dominated by the naive B cell, and a significant decrease in the proportion of memory B cells and plasmablasts. Regarding T cell markers related to CAR T therapy, the high proportion of naive T cell (CD45RA+CD27+) and central memory T cell (CD45RA-CD62L+CD27+) subsets before infusion indicate stronger anti-tumor efficacy; The initial expression of transcription factors associated with early memory differentiation on patients’ CAR T cells, such as T cell factor 7 (TCF7) and lymphoid enhancer‐binding factor 1 (LEF1), suggest that these patients may be sensitive to CAR T therapy. After infusion, high expression of T cell activation markers (CD25, CD69 and CD137), and exhaustion markers (CD57, PD-1, and Tim-3) indicate that T cells are in a state of dysfunction, with limited expansion, cytokine secretion and cell killing capabilities. Safety markers, including effector cytokines secreted by CAR T cells [interleukin(IL)-2 and IFN-γ] and cytokines produced by monocytes and macrophages (IL-1 and IL-8), can be used to monitor the most common toxicities and side-effects of CAR T-cell therapies, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).High levels of serum macrophage inflammatory protein-1α (MIP-1α) are of high value for predicting the risk of severe CRS and ICANS after CAR T-cell therapy. In addition, haematotoxicity markers include baseline platelet count and absolute neutrophil count, and an infection-related prediction model consisting of IL-8, IFN-γ and IL-1β are effective in predicting the risk of severe infection in patients after infusion.The design of the CAR receptor structure, the chemotherapeutic modality used to remove the lymphocytes, as well as the choice of treatments that the patient had received and the autoimmune status, all affect the efficacy and safety. A comprehensive and standardised testing and evaluation system should be included in current and future clinical studies to provide a comparative standard for the use of CAR T-cell therapy in autoimmune diseases such as SLE.
WANG Yiyang , Lü Liangjing . Potential biomarkers for prediction of the efficacy and safety of CAR T cell treatment in systemic lupus erythematosus[J]. Journal of Diagnostics Concepts & Practice, 2024 , 23(03) : 263 -269 . DOI: 10.16150/j.1671-2870.2024.03.003
[1] | BAKER D J, ARANY Z, BAUR J A, et al. CAR T therapy beyond cancer: the evolution of a living drug[J]. Nature, 2023, 619(7971):707-715. |
[2] | MALDINI C R, ELLIS G I, RILEY J L. CAR T cells for infection, autoimmunity and allotransplantation[J]. Nat Rev Immunol, 2018, 18(10):605-616. |
[3] | DRIVER C B, ISHIMORI M, WEISMAN M H. The B cell in systemic lupus erythaematosus: a rational target for more effective therapy[J]. Ann Rheum Dis, 2008, 67(10):1374-1381. |
[4] | MOUGIAKAKOS D, KR?NKE G, V?LKL S, et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus[J]. N Engl J Med, 2021, 385(6):567-569. |
[5] | MACKENSEN A, MüLLER F, MOUGIAKAKOS D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus[J]. Nat Med, 2022, 28(10):2124-2132. |
[6] | MüLLER F, TAUBMANN J, BUCCI L, et al. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up[J]. N Engl J Med, 2024, 390(8):687-700. |
[7] | WANG Z, HAN W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy[J]. Biomark Res, 2018, 6:4. |
[8] | TAN J Y, LOW M H, CHEN Y, et al. CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity[J]. Int J Mol Sci, 2022, 23(13):6931. |
[9] | LEVSTEK L, JAN?I? L, IHAN A, et al. Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives[J]. Front Immunol, 2024, 15:1378944. |
[10] | LARSON R C, MAUS M V. Recent advances and discoveries in the mechanisms and functions of CAR T cells[J]. Nat Rev Cancer, 2021, 21(3):145-161. |
[11] | LABANIEH L, MACKALL C L. CAR immune cells: design principles, resistance and the next generation[J]. Nature, 2023, 614(7949):635-648. |
[12] | XIAO X, HUANG S, CHEN S, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies[J]. J Exp Clin Cancer Res, 2021, 40(1):367. |
[13] | FLUGEL C L, MAJZNER R G, KRENCIUTE G, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours[J]. Nat Rev Clin Oncol, 2023, 20(1):49-62. |
[14] | SCHUBERT M L, SCHMITT M, WANG L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy[J]. Ann Oncol, 2021, 32(1):34-48. |
[15] | ARBITMAN L, FURIE R, VASHISTHA H. B cell-targeted therapies in systemic lupus erythematosus[J]. J Autoimmun, 2022, 132:102873. |
[16] | KANSAL R, RICHARDSON N, NEELI I, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus[J]. Sci Transl Med, 2019, 11(482):eaav1648. |
[17] | JIN X, XU Q, PU C, et al. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus[J]. Cell Mol Immunol, 2021, 18(8):1896-1903. |
[18] | WANG W, HE S, ZHANG W, et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial[J/OL]. Ann Rheum Dis.[2024-04-23]. https://pubmed.ncbi.nlm.nih.gov/38777376/. |
[19] | LINDBLOM J, MOHAN C, PARODIS I. Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights[J]. Curr Opin Rheumatol, 2022, 34(2):139-149. |
[20] | TAUBMANN J, MüLLER F, YALCIN MUTLU M, et al. CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus[J]. Arthritis Rheumatol, 2024, 76(4):497-504. |
[21] | JACOBI A M, REITER K, MACKAY M, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95[J]. Arthritis Rheum, 2008, 58(6):1762-1773. |
[22] | TIPTON C M, FUCILE C F, DARCE J, et al. Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus[J]. Nat Immunol, 2015, 16(7):755-765. |
[23] | FRAIETTA J A, LACEY S F, ORLANDO E J, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia[J]. Nat Med. 2018; 24(5):563-571. |
[24] | TURICEK D P, GIORDANI V M, MORALY J, et al. CAR T-cell detection scoping review: an essential biomarker in critical need of standardization[J]. J Immunother Cancer, 2023, 11(5):e006596. |
[25] | KASAKOVSKI D, XU L, LI Y. T cell senescence and CAR-T cell exhaustion in hematological malignancies[J]. J Hematol Oncol, 2018, 11(1):91. |
[26] | ARCANGELI S, FALCONE L, CAMISA B, et al. Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients[J]. Front Immunol, 2020, 11:1217. |
[27] | SIMULA L, OLLIVIER E, ICARD P, et al. Immune Checkpoint Proteins, Metabolism and Adhesion Molecules: Overlooked Determinants of CAR T-Cell Migration?[J]. Cells, 2022, 11(11):1854. |
[28] | ANSELL S M, MAURER M J, ZIESMER S C, et al. Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients[J]. Am J Hematol, 2012, 87(9):865-869. |
[29] | TIAN Y, WEN C, ZHANG Z, et al. CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy[J]. Cancer Immunol Immunother. 2022; 71(11):2663-2675. |
[30] | WANG G, ZHANG Z, ZHONG K, et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma[J]. Mol Ther, 2023, 31(1):134-153. |
[31] | LIU D, ZHAO J. Cytokine release syndrome: grading, modeling, and new therapy[J]. J Hematol Oncol, 2018, 11(1):121. |
[32] | HONG R, HU Y, HUANG H. Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction. Front Immunol. 2021; 12:627764. |
[33] | TEACHEY D T, LACEY S F, SHAW P A, et al. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia[J]. Cancer Discov, 2016, 6(6):664-679. |
[34] | NORELLI M, CAMISA B, BARBIERA G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells[J]. Nat Med, 2018, 24(6):739-748. |
[35] | HAY K A, HANAFI L A, LI D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy[J]. Blood, 2017, 130(21):2295-2306. |
[36] | SANTOMASSO B D, PARK J H, SALLOUM D, et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia[J]. Cancer Discov, 2018, 8(8):958-971. |
[37] | MORENO-CASTA?O A B, FERNáNDEZ S, VENTOSA H, et al. Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis[J]. J Immunother Cancer, 2023, 11(4):e006365. |
[38] | FRIED S, AVIGDOR A, BIELORAI B, et al. Early and late hematologic toxicity following CD19 CAR-T cells[J]. Bone Marrow Transplant, 2019, 54(10):1643-1650. |
[39] | REJESKI K, PEREZ A, SESQUES P, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma[J]. Blood, 2021, 138(24):2499-2513. |
[40] | HILL J A, LI D, HAY K A, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy[J]. Blood, 2018, 131(1):121-130. |
[41] | LOCKE F L, GHOBADI A, JACOBSON C A, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial[J]. Lancet Oncol, 2019, 20(1):31-42. |
[42] | LUO H, WANG N, HUANG L, et al. Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy[J]. J Immunother Cancer, 2019, 7(1):271. |
[43] | SANDLER R D, TATTERSALL R S, SCHOEMANS H, et al. Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)[J]. Front Immunol, 2020, 11:524. |
[44] | NEELAPU S S, TUMMALA S, KEBRIAEI P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities[J]. Nat Rev Clin Oncol, 2018, 15(1):47-62. |
/
〈 |
|
〉 |